Persistent low-level β-hCG with a hypervascular intrauterine mass after medical abortion mimicking GTN: a diagnostic dilemma
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262141Keywords:
Persistent β-hCG, Retained products of conception, Gestational trophoblastic neoplasia, Uterine vascular lesion, Medical abortion complicationAbstract
Persistent elevation or plateau of serum beta-human chorionic gonadotropin (β-hCG) following abortion raises suspicion for gestational trophoblastic neoplasia (GTN). However, benign conditions such as retained products of conception (RPOC) and uterine vascular lesions may present with similar biochemical and imaging findings, creating a diagnostic challenge. A 27-year-old multiparous woman presented with persistent amenorrhea following unsupervised medical abortion. Ultrasound revealed heterogeneous intrauterine contents with increased vascularity. Serial β-hCG levels showed a plateauing trend. Due to suspicion of GTN, she received single-dose followed by multi-dose methotrexate therapy. Although β-hCG levels declined, they failed to normalize and imaging demonstrated a persistent hypervascular intrauterine mass. Considering the risk of haemorrhage with uterine instrumentation and the inability to exclude malignancy, total abdominal hysterectomy was performed. Histopathology revealed necrosed retained products of conception. Postoperatively, β-hCG levels became undetectable. Persistent low-level β-hCG with a hypervascular intrauterine lesion may mimic GTN. In selected patients with completed childbearing and diagnostic uncertainty, hysterectomy may serve as both a diagnostic and therapeutic intervention.
References
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(1):86-93.
Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021;137(2):355-70.
Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112:654-62.
Braga A, Mora P, De Melo AC, Nogueira-Rodrigues A, Amim-Junior J, Rezende-Filho J, et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol. 2019;10(2):28-37.
Sellmyer MA, Desser TS, Maturen KE, Jeffrey RB, Kamaya A. Physiologic, histologic, and imaging features of retained products of conception. Radiographics. 2013;33(3):781-96.
Kamaya A, Petrovitch I, Chen B, Frederick CE, Jeffrey RB. Retained products of conception: spectrum of color Doppler findings. J Ultrasound Med. 2009;28(8):1031-41.
Timmerman D, Van den Bosch T, Peeraer K, Debrouwere E, Van Schoubroeck D, Stockx L, et al. Vascular malformations in the uterus: ultrasonographic diagnosis and conservative management. Eur J Obstet Gynecol Reprod Biol. 2000;92(1):171-8.
Hancock BW, Tidy J. Placental site trophoblastic tumour and epithelioid trophoblastic tumour. Best Pract Res Clin Obstet Gynaecol. 2021;74:131-48.
Lok C, Frijstein M, Van Trommel N. Clinical presentation and diagnosis of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2021;74:42-52.
Peitsidis P, Manolakos E, Tsekoura V, Kreienberg R, Schwentner L. Uterine arteriovenous malformations induced after diagnostic curettage: a systematic review. Arch Gynecol Obstet. 2011;284(5):1137-51.
Durfee SM, Frates MC, Luong A, Benson CB. The sonographic and color Doppler features of retained products of conception. J Ultrasound Med. 2005;24(9):1181-6.
Downloads
Published
How to Cite
Issue
Section
